Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Tafinlar

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BackgroundThe use of molecularly targeted therapy is becoming widespread in oncology. These agents cause tumour-specific genetic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2016
Review
2016
The RAS-RAF-MEK1/2-ERK1/2 pathway is a key signal transduction pathway in the cells. Critically, it remains constitutively active… Expand
  • figure 1
  • table 2
  • table 3
  • table 3
  • figure 2
Is this relevant?
2016
2016
This analysis presents anticancer drug combinations that contain two or more targeted agents and discusses their impact on… Expand
  • table 1
  • figure 1
Is this relevant?
2016
2016
Dabrafenib (Tafinlar(®)) and trametinib (Mekinist(®)) are registered for the treatment of patients with BRAF V600 mutation… Expand
Is this relevant?
2016
2016
Dabrafenib (Tafinlar) was approved in 2013 by the FDA as a selective single agent treatment for patients with BRAFV600E mutation… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
2015
2015
Despite the continuously increasing incidence of melanoma, over decades the therapy has barely changed. However, since 2011 the… Expand
Is this relevant?
Review
2015
Review
2015
  • Michael A. Davies
  • Clinical advances in hematology & oncology : H&O
  • 2015
  • Corpus ID: 21175472
MD The US Food Administration (FDA) has approved several molecularly targeted agents for use in patients with metastatic melanoma… Expand
Is this relevant?
2014
2014
Dear Editor, Hairy cell leukemia (HCL) is a mature B-cell lymphoid cancer that can be treated successfully in the majority of… Expand
  • figure 1
  • figure 2
Is this relevant?
2014
2014
Webster and Mentzer discuss the market landscape for malignant melanoma — a cancer for which treatment options have broadened… Expand
  • figure 1
Is this relevant?
2013
2013
  • Ken Garber
  • Nature biotechnology
  • 2013
  • Corpus ID: 205270372
On July 9, GlaxoSmithKline of London filed an application with the US Food and Drug Administration (FDA) seeking approval of BRAF… Expand
  • table 1
Is this relevant?